Review
Copyright ©The Author(s) 2017.
World J Diabetes. May 15, 2017; 8(5): 172-186
Published online May 15, 2017. doi: 10.4239/wjd.v8.i5.172
Figure 2
Figure 2 Cardiovascular outcomes in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome (A) and cardiovascular safety trial of empagliflozin (B) studies according to estimated glomerular filtration rate. MACE: Major adverse cardiovascular event; eGFR: Estimated glomerular filtration rate; HR: Hazard ratio.